We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

99 hedge funds and large institutions have $485M invested in Epizyme, Inc in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

81% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 21

9% more funds holding

Funds holding: 9199 (+8)

13% less capital invested

Capital invested by funds: $556M → $485M (-$71M)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

55% less call options, than puts

Call options by funds: $20K | Put options by funds: $44K

Holders
99
Holders Change
+8
Holders Change %
+8.79%
% of All Funds
2.64%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.13%
New
17
Increased
38
Reduced
21
Closed
9
Calls
$20K
Puts
$44K
Net Calls
-$24K
Net Calls Change
-$22K
Name Holding Trade Value Shares
Change
Change in
Stake
CIM
76
CIM Investment Management
Pennsylvania
$113K +$123K +11,055 New
DTL
77
Dynamic Technology Lab
Singapore
$104K +$114K +10,208 New
BG
78
BlackRock Group
United Kingdom
$103K -$1.37K -123 -1%
Citigroup
79
Citigroup
New York
$98K -$284K -25,458 -73%
Bank of America
80
Bank of America
North Carolina
$87K +$66.3K +5,950 +238%
Legal & General Group
81
Legal & General Group
United Kingdom
$78K
Teacher Retirement System of Texas
82
Teacher Retirement System of Texas
Texas
$55K +$7.28K +653 +14%
Canada Life
83
Canada Life
Manitoba, Canada
$49K
Royal Bank of Canada
84
Royal Bank of Canada
Ontario, Canada
$48K -$1.7K -152 -3%
EA
85
Emerald Acquisition
Washington
$46K +$50.2K +4,500 New
BlackRock
86
BlackRock
New York
$45K +$13.5K +1,214 +39%
UBS Group
87
UBS Group
Switzerland
$32K +$2K +179 +6%
LWCFA
88
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$31K -$27.9K -2,500 -45%
FANJ
89
Financial Architects (New Jersey)
New Jersey
$26K
CG
90
Cutler Group
California
$23K +$5.58K +500 +28%
US Bancorp
91
US Bancorp
Minnesota
$20K
BNP Paribas Financial Markets
92
BNP Paribas Financial Markets
France
$16.7K +$18.2K +1,634 New
Simplex Trading
93
Simplex Trading
Illinois
$14K +$15.8K +1,414 New
Zurich Cantonal Bank
94
Zurich Cantonal Bank
Switzerland
$4K
Bank of Montreal
95
Bank of Montreal
Ontario, Canada
$2K -$736 -66 -29%
TRCT
96
Tower Research Capital (TRC)
New York
$2K +$1.17K +105 +111%
Barclays
97
Barclays
United Kingdom
$1K -$23.5K -2,107 -97%
AIM
98
Acrospire Investment Management
Illinois
$1K +$1.11K +100 New
OPPM
99
Opus Point Partners Management
New York
-$2.3M -189,564 Closed
AL
100
Airain Ltd
Guernsey
-$334K -27,519 Closed

EPZM Hedge Fund Activity: Q2 2016 in Review

99 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2016, worth a combined $485M — down 13% from $556M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EPZM positions and 9 closed out — a net gain of 8 holders — while 38 added to existing stakes and 21 trimmed.

The largest buyer was CQS Cayman, opening a new position worth an estimated $7.08M. The largest seller was EcoR1 Capital, cutting an estimated $9.41M.

  • 99 institutional investors held Epizyme, Inc (EPZM) as of Q2 2016, up from 91 in Q1 2016.
  • Funds reported $485M of Epizyme, Inc stock for Q2 2016, down 13% quarter-over-quarter.
  • 17 funds opened new Epizyme, Inc positions in Q2 2016 and 9 closed out, a net change of +8 holders.
  • The largest Epizyme, Inc buyer in Q2 2016 was CQS Cayman, an estimated $7.08M added.
  • The largest Epizyme, Inc seller in Q2 2016 was EcoR1 Capital, an estimated $9.41M sold.

Based on aggregated 13F filings for Q2 2016.